Skip to content
Top Menu
  • Log In
  • Register
  • Facebook
  • Twitter
  • LinkedIn
MyChesCo

MyChesCo

Chester County News and Community Website

  • Communities
    • Avondale
    • Berwyn
    • Coatesville
    • Cochranville
    • Devon
    • Downingtown
    • Exton
    • Honey Brook
    • Kennett Square
    • Malvern
    • Oxford
    • Paoli
    • Parkesburg
    • Phoenixville
    • Spring City
    • Toughkenamon
    • West Chester
    • West Grove
  • Education
    • Chester County Intermediate Unit
    • School Districts
      • Avon Grove School District
      • Coatesville Area School District
      • Downingtown Area School District
      • Great Valley School District
      • Kennett Consolidated School District
      • Octorara Area School District
      • Owen J. Roberts School District
      • Oxford Area School District
      • Phoenixville Area School District
      • Spring-Ford Area School District
      • Tredyffrin-Easttown School District
      • Twin Valley School District
      • Unionville-Chadds Ford School District
      • West Chester Area School District
    • Charter Schools
    • Independent Schools
    • Colleges and Universities
    • Chester County Library System
  • News
    • Traffic
    • Weather
    • Business
    • Health / Medical
    • National
    • Pennsylvania
    • Sports
  • Entertainment
  • Lifestyle
  • Tools
    • Members
    • Groups
    • Submit an Article
    • Contact Us
    • Signup for Newsletter
    • Contests and Giveaways
    • Gas Prices
    • Register
    • Log In
  • About
    • MyChesCo
    • Writing for Us
    • Advertising with Us
    • Contacting Us
    • Citizen Journalism
    • Submitting Articles
    • Starting a Group
    • How to Support Us
    • Terms of Service
    • Privacy Policy
    • DMCA Policy
    • AI Disclosure
  • Shop

PleoPharma

PleoPharma
Research

PleoPharma Presents Promising Phase 2b Data on PP-01 for Cannabis Withdrawal

June 20, 2025June 19, 2025 - by Timothy Alexander

PHOENIXVILLE, PA — PleoPharma, Inc. shared encouraging findings from its Phase 2b clinical trial of PP-01, a novel treatment for Cannabis Withdrawal Syndrome (CWS), during the 2025 annual meeting of …

PleoPharma Presents Promising Phase 2b Data on PP-01 for Cannabis Withdrawal Read More

PleoPharma
Business

PleoPharma Secures Patent for Treating Sleep Disturbances in Cannabis Withdrawal

April 21, 2025April 20, 2025 - by Timothy Alexander

PHOENIXVILLE, PA — PleoPharma, Inc. has announced a significant intellectual property milestone with the issuance of its third U.S. patent, aimed at addressing sleep disturbances linked to cannabis withdrawal syndrome …

PleoPharma Secures Patent for Treating Sleep Disturbances in Cannabis Withdrawal Read More
PleoPharma
Research

FDA Grants Fast Track Designation to PleoPharma’s PP-01 for Cannabis Withdrawal Syndrome

February 15, 2025February 14, 2025 - by Timothy Alexander

PHOENIXVILLE, PA — PleoPharma, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PP-01, the company’s lead investigational asset aimed at mitigating Cannabis …

FDA Grants Fast Track Designation to PleoPharma’s PP-01 for Cannabis Withdrawal Syndrome Read More

PleoPharma
Research

PleoPharma Showcases Promising Results in Study on Cannabis Withdrawal Syndrome

November 24, 2024November 24, 2024 - by Timothy Alexander

PHOENIXVILLE, PA – PleoPharma, Inc. recently presented new data from its Phase 1b study on Cannabis Withdrawal Syndrome (CWS) at the American Academy of Addiction Psychiatry’s annual meeting in Naples, …

PleoPharma Showcases Promising Results in Study on Cannabis Withdrawal Syndrome Read More
PleoPharma
Business

PleoPharma Secures Key Patents for Cannabis Withdrawal Treatment

October 13, 2024October 12, 2024 - by Timothy Alexander

PHOENIXVILLE, PA — PleoPharma, Inc. has announced the issuance of two critical U.S. patents that bolster its efforts to treat cannabis withdrawal syndrome (CWS). These patents, U.S. Patent 11,197,846 and U.S. …

PleoPharma Secures Key Patents for Cannabis Withdrawal Treatment Read More

PleoPharma
Research

PleoPharma’s PP-01 Shows Promise in Treating Cannabis Withdrawal Syndrome

September 9, 2024September 9, 2024 - by Timothy Alexander

PHOENIXVILLE, PA — PleoPharma, Inc. has announced promising results from a Phase 2b study evaluating its leading drug candidate, PP-01, intended for mitigating Cannabis Withdrawal Syndrome. Conducted across 22 US addiction …

PleoPharma’s PP-01 Shows Promise in Treating Cannabis Withdrawal Syndrome Read More

Trending News

  • Infant Killed After Police Pursuit Ends in Fiery Wilmington Crash

  • Felony Warrants, Traffic Stop, and New Charges: Arrest in Parkesburg Raises Serious Allegations

  • AbbeyFest Expected to Draw 6,000 to Doylestown this Saturday

  • West Chester Man Accused of Brutal Assault and Rape in Early Morning Attack

  • From DUI Stop to Stolen Vehicle Allegations: Kennett Square Man Faces Multiple Charges

Subscribe for Updates

Follow Us

  • Facebook
  • X
  • LinkedIn
  • Google
  • RSS Feed

Tools

  • Members
  • Newsletter
  • Events
  • Groups
  • Guest Articles
  • Coupon Center
  • Gas Prices
  • Log In
  • Register

About Us

  • About MyChesCo
  • Advertise
  • Contact Us
  • Support Us
  • Write for Us
  • Terms of Service
  • Privacy Policy
  • DMCA Policy
  • Affiliate Disclaimer

Recommended Reading

Police News

Infant Killed After Police Pursuit Ends in Fiery Wilmington Crash

September 17, 2025September 17, 2025

Waylon William Cornog

Felony Warrants, Traffic Stop, and New Charges: Arrest in Parkesburg Raises Serious Allegations

September 17, 2025September 17, 2025

Ariel Delgadillo

West Chester Man Accused of Brutal Assault and Rape in Early Morning Attack

September 17, 2025September 17, 2025

Copyright © 2025 MyChesCo.